GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Phio Pharmaceuticals Corp (FRA:44R3) » Definitions » Short Percentage of Float

Phio Pharmaceuticals (FRA:44R3) Short Percentage of Float


View and export this data going back to 2014. Start your Free Trial

What is Phio Pharmaceuticals Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Phio Pharmaceuticals's Short Percentage of Float

For the Biotechnology subindustry, Phio Pharmaceuticals's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Phio Pharmaceuticals's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Phio Pharmaceuticals's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Phio Pharmaceuticals's Short Percentage of Float falls into.


Phio Pharmaceuticals (FRA:44R3) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Phio Pharmaceuticals Corp (FRA:44R3) » Definitions » Short Percentage of Float
Comparable Companies
SLRX PXMD SNPX RVLPQ NVIV THAR IVBT HSTC SCNI ATNF OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
PHIO:USA
Address
257 Simarano Drive, Suite 101, Marlborough, MA, USA, 01752
Website
https://www.phiopharma.com
Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipeline products include PH-762, PH-804, PH-790, and others.

Phio Pharmaceuticals (FRA:44R3) Headlines

No Headlines